
Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Investment analysts at Atb Cap Markets dropped their FY2025 EPS estimates for shares of Curaleaf in a report released on Thursday, August 7th. Atb Cap Markets analyst F. Gomes now forecasts that the company will post earnings per share of ($0.29) for the year, down from their previous estimate of ($0.28). The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Atb Cap Markets also issued estimates for Curaleaf's FY2027 earnings at ($0.18) EPS, FY2028 earnings at ($0.13) EPS and FY2029 earnings at ($0.11) EPS.
Separately, Cormark raised shares of Curaleaf from a "hold" rating to a "moderate buy" rating in a research report on Friday, August 8th.
Get Our Latest Stock Analysis on Curaleaf
Curaleaf Stock Down 1.9%
CURLF traded down $0.06 during trading on Monday, reaching $2.88. The company had a trading volume of 255,725 shares, compared to its average volume of 762,689. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.47 and a quick ratio of 0.70. Curaleaf has a 12 month low of $0.68 and a 12 month high of $3.58. The business's fifty day moving average price is $1.23 and its 200 day moving average price is $1.10. The company has a market cap of $1.93 billion, a P/E ratio of -9.00 and a beta of 0.69.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative net margin of 18.08% and a negative return on equity of 14.61%.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Recommended Stories

Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.